SOURCE: Xtalks

Xtalks Webinars

October 20, 2015 07:00 ET

Each Hour Counts: Physician and Pharmacist Perspectives on the Value of Rapid Blood Culture Testing

TORONTO, ON--(Marketwired - October 20, 2015) - On Thursday, October 29th, Nanosphere and Xtalks will host a complimentary, P.A.C.E. accredited webinar on the clinical impact of rapid blood culture testing. This webinar will review the current guidelines for the management of septic patients and discuss the impact that rapid blood culture diagnostics are having on the clinician's ability to manage patients with bloodstream infections and antimicrobial stewardship initiatives.

Sepsis, the host's immune response to a serious infection, can be triggered by bacteria or fungi circulating in the bloodstream. Sepsis that results from bacteremia causes nearly 500,000 hospitalizations each year in the U.S. and accounts for 11% of intensive care unit (ICU) admissions.1 Mortality associated with these infections is extremely high and can range anywhere from 25% to 80%.2 Septicemia is not only burdensome due to its high associated rates of mortality, but also because of the excessive cost associated with treating this disease. Septicemia has consistently ranked as the most expensive condition to treat in U.S. hospitals. In 2011, treatment of septicemia resulted in an aggregate cost of $20.3 billion, which was 5.2 percent of the total aggregate cost of all hospitalizations.3 When compared to the average cost of a patient admitted to the intensive care unit (ICU) who does not acquire a bloodstream infection, those that do remain in the ICU 8 days longer and 24 days in the hospital longer, resulting in $36,000 to $40,000 in additional costs per patient.4

Time to appropriate therapy has been proven to be a critical determinant for patient outcomes. Kumar et al. demonstrated a 7.6% mean decrease in survival rates for each hour that optimal therapy is delayed following the start of sepsis-related hypotension.5 Conventional culture-based diagnostics, which remain the gold standard for identification of the bloodstream pathogens, are not ideal as they are associated with very slow turnaround times which can stretch upwards of 3-4 days. With long time-to-identification, a patient might remain on the inappropriate empiric therapy, predisposing them to a higher risk of mortality. Patients in the ICU receiving inadequate antimicrobial treatment for bloodstream infections have an associated mortality rate of 61.9%, while patients receiving appropriate therapy only have an associated mortality rate of 28.4%.6

Molecular based diagnostic tests have emerged as the first viable solution to culture for the detection of bloodstream pathogens. Rapid diagnostic tests for bloodstream infections have been able to accelerate the time to bacterial identification and antimicrobial resistance detection by as many as 2 days over traditional phenotypic methods, allowing clinicians the opportunity to place the patient on the optimal therapy much quicker. Clinical implementation of these tests has been associated with improved patient outcomes, enhanced antimicrobial stewardship, more effective infection control, and has led to reduction in healthcare costs.7-12 The increase in adoption of rapid sepsis diagnostic tests has been driven, in large part, by clinical studies that have captured the clinical and economic impact of these tests.

Featured Speakers:

  • Marin H. Kollef, M.D., FACP, FCCP, Professor, Medicine, Division of Pulmonary and Critical Care Medicine, Director, Medical Intensive Care Unit, Barnes-Jewish Hospital, Director, Respiratory Care Services, Barnes-Jewish Hospital
  • Brad J. Crane, PharmD, BCPS, Clinical Pharmacy Specialist, Critical Care/Infectious Diseases, Director, Antimicrobial Stewardship Program, Blount Memorial Hospital

To register or learn more about this complimentary event visit: Each Hour Counts: Physician and Pharmacist Perspectives on the Value of Rapid Blood Culture Testing

P.A.C.E. Accreditation

Xtalks is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program -- Attendees will receive further details after the event.

About Nanosphere

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplex molecular diagnostic test. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business.

For more information visit www.nanosphere.us.

Contact:
Zack Crowther, Director of Marketing
Nanosphere, Inc.
+1 312-919-2291
zcrowther@nanosphere.us

About Xtalks

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

References

[1] Angus DC, Wax RS. Epidemiology of Sepsis: An Update. Crit Care Med 2011; 29: S109-S116.
[2] Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
[3] Torio CM, Andrews RM. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer: HCUP Statistical Brief #160. 2013. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.pdf (Accessed September 2015).
[4] Pittet D, Tarara D, Wenzel RP. Nosocomial Bloodstream Infection in Critically Ill Patients: Excess Length of Stay, Extra Costs, and Attributable Mortality. JAMA 1994; 271: 1598-1601.
[5] Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596.
[6] Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-155.
[7] Sango A, McCarter YS, Johnson D, Ferreira J, Guzman N, Jankowski CA. Stewardship Approach for Optimizing Antimicrobial Therapy through Use of a Rapid Microarray Assay on Blood Culture Positive for Enterococcus Species. J. Clin. Microbiol. 2013; 51(12): 4008-11.
[8] Buchan BW, Ginocchio CC, Manii R, Cavagnolo R, Pancholi P, Swyers L, Thomson RB Jr, Anderson C, Kaul K, Ledeboer NA. Multiplex Identification of Gram-Positive Bacteria and Resistance Determinants Directly from Positive Blood Culture Broths: Evaluation of an Automated Microarray-Based Nucleic Acid Test. PLoS Medicine. 2013.
[9] Wojewoda CM, Sercia L, Navas M, Touhy M, Wison D, Hall GS, Procop GW, Richter SS. Evaluation of the Verigene Gram-Positive Blood Culture Nucleic Acid Test for Rapid Detection of Bacteria and Resistance Determinants. Journal of Clinical Microbiology. 2013; 51(4): 1188-92.
[10] Alby K, Daniels LM, Weber DJ, Miller MB. Development of a Treatment Algorithm for Streptococci and Enterococci from Positive Blood Cultures Identified with the Verigene Gram-Positive Blood Culture Assay. Journal of Clinical Microbiology. 2013; 51(11): 3869-71.
[11] Mancini N, Infurnari L, Ghidoli N, Valzano G, Clementi N, Burioni R, Clementi M. Potential Impact of a Microarray-Based Nucleic Acid Assay for Rapid Detection of Gram-Negative Bacteria and Resistance Markers in Positive Blood Cultures. J. Clin. Microbiol. 2014; 52(4). 1242-5.
[12] Box MJ, Sullivan EL, Ortwine KN, Paramenter MA, Quigley MM, Aguilar-Higgins LM, MacIntosh CL, Goerke KF, Lim RA. Outcomes of Rapid Identification for Gram-Positive Bacteremia in Combination with Antibiotic Stewardship at a Community-Based Hospital System. Pharmacotherapy 2015; 35(3): 269-76.

Image Available: http://www.marketwire.com/library/MwGo/2015/10/19/11G068147/Images/Nano_logo_300-1125224536675.jpg
Image Available: http://www.marketwire.com/library/MwGo/2015/10/19/11G068147/Images/PACE_Logo-1163389360782.jpg

Contact Information